Clarithro is a medicine containing the active ingredient(s) clarithromycin. On this page you will find out more about Clarithro, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: clarithromycin
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Clarithro 250 mg film-coated tablet, 14
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
For use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute streptococcal pharyngitis. Community acquired pneumonia due to Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella pneumophilia and Strep. pneumoniae. Uncomplicated skin and skin structure infections due to Staph. aureus or Strep. pyogenes. Disseminated or localised mycobacterial infections due to M. avium or M. intracellulare and skin and skin structure infections due to M. chelonae. Clarithromycin should be used in combination with other antimycobacterial agents. Prevention of disseminated M. avium complex infection in HIV infected adults with CD4 lymphocyte counts < 75 cells/mm3. Disseminated infection due to M. avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis. Acute bacterial exacerbation of chronic bronchitis due to H. influenzae, Moraxella catarrhalis or Strep. pneumoniae. Combination therapy for the treatment of peptic ulcer disease associated with H. pylori infection. For use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute streptococcal pharyngitis and tonsillitis caused by Strep. pyogenes. Community acquired pneumonia including infections due to Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumophilia. Skin and skin structure infections (e.g. impetigo). Disseminated or localised infections due to M. avium or M. intracellulare in immunocompromised children, including those with HIV infection or AIDS. Acute otitis media. Note. Penicillins are the drug of first choice in the treatment of acute otitis media. Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. Clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of Streptococci from the nasopharynx, however substantial data establishing the efficacy of Clarithromycin in the subsequent prevention of rheumatic fever are not available at present. There is insufficient evidence of efficacy to support the use of Clarithromycin in acute bronchitis in young children. The data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.
Table of characteristics
|Visual appearance||Yellow, oval film-coated tablet 7.8mm x 14.9mm|
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
100 tablets: Prescription Only Medicine, or Prescription Animal Remedy
14 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 March 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.